Posterior reversible encephalopathy syndrome due to combination of vemurafenib and cobimetinib for metastatic melanoma

Pigment Cell Melanoma Res. 2017 Mar;30(2):262-264. doi: 10.1111/pcmr.12562. Epub 2017 Mar 6.

Authors

Feriel Boukari¹, Pierre Michel Dugourd¹, Madleen Chassang², Lydiane Mondot³, Thierry Passeron^{1

4}, Jean-Philippe Lacour¹, Henri Montaudie¹

Affiliations

¹ Department of Dermatology, University of Nice Sophia Antipolis, Nice, France.
² Department of Radiology, University of Nice Sophia Antipolis, Nice, France.
³ Department of Radiology, Pasteur Hospital, University of Nice Sophia Antipolis, Nice, France.
⁴ INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, Team 12, Nice, France.

PMID: 27885826
DOI: 10.1111/pcmr.12562

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Azetidines / adverse effects*
Brain / diagnostic imaging
Disease Progression
Humans
Indoles / adverse effects*
Lymphatic Metastasis
Magnetic Resonance Imaging
Male
Melanoma / complications*
Melanoma / drug therapy
Piperidines / adverse effects*
Posterior Leukoencephalopathy Syndrome / chemically induced*
Posterior Leukoencephalopathy Syndrome / diagnosis
Proto-Oncogene Proteins B-raf / metabolism
Skin Neoplasms / complications*
Skin Neoplasms / drug therapy
Sulfonamides / adverse effects*
Vemurafenib

Substances

Azetidines
Indoles
Piperidines
Sulfonamides
Vemurafenib
Proto-Oncogene Proteins B-raf
cobimetinib